Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.

<h4>Background/purpose</h4>To date, studies examining polymicrobial infections in ocular disease have mostly been limited to keratitis or endophthalmitis. We characterized polybacterial infections compared to monobacterial infections in prior clinical studies evaluating besifloxacin opht...

Full description

Bibliographic Details
Main Authors: Heleen H DeCory, Christine M Sanfilippo, Howard M Proskin, Joseph M Blondeau
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0237603
id doaj-27761c3056754d6ca5247f0bb0136b46
record_format Article
spelling doaj-27761c3056754d6ca5247f0bb0136b462021-03-04T11:14:32ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01158e023760310.1371/journal.pone.0237603Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.Heleen H DeCoryChristine M SanfilippoHoward M ProskinJoseph M Blondeau<h4>Background/purpose</h4>To date, studies examining polymicrobial infections in ocular disease have mostly been limited to keratitis or endophthalmitis. We characterized polybacterial infections compared to monobacterial infections in prior clinical studies evaluating besifloxacin ophthalmic suspension 0.6% for the treatment of bacterial conjunctivitis and report on associated microbiological outcomes.<h4>Methods</h4>In this post-hoc analysis, microbiological data for subjects with conjunctivitis due to one or more than one bacterial species in three previous studies (two vehicle-, one active-controlled) of besifloxacin were extracted. Bacterial species identified at baseline were deemed causative if their colony count equaled or exceeded species-specific prespecified threshold criteria. In subjects with polybacterial infections, the fold-increase over threshold was used to rank order the contribution of individual species. Baseline pathogens and their minimum inhibitory concentrations (MICs) for common ophthalmic antibiotics were compared by infection type, as were microbial eradication rates following treatment with besifloxacin.<h4>Results</h4>Of 1041 subjects with culture-confirmed conjunctivitis, 17% had polybacterial and 83% had monobacterial conjunctivitis at baseline. In polybacterial compared to monobacterial infections, Haemophilus influenzae and Streptococcus pneumoniae were identified less frequently as the dominant infecting species (P = 0.042 and P<0.001, respectively), whereas Streptococcus mitis/S. mitis group was identified more frequently as dominant (P<0.001). Viral coinfection was also identified more frequently in polybacterial infections (P<0.001). Staphylococcus aureus was the most common coinfecting species in polybacterial infections and the second most common dominant species in such infections. With few exceptions, MICs for individual species were comparable regardless of infection type. Clinical microbial eradication rates with besifloxacin were high regardless of infection type (P≤0.016 vs vehicle at follow-up visits).<h4>Conclusions</h4>Approximately one in five subjects with bacterial conjunctivitis are infected with more than one bacterial species underscoring the need for a broad-spectrum antibiotic for such infections. Besifloxacin treatment resulted in robust eradication rates of these infections comparable to monobacterial infections.<h4>Trial registration</h4>NCT000622908, NCT00347932, NCT00348348.https://doi.org/10.1371/journal.pone.0237603
collection DOAJ
language English
format Article
sources DOAJ
author Heleen H DeCory
Christine M Sanfilippo
Howard M Proskin
Joseph M Blondeau
spellingShingle Heleen H DeCory
Christine M Sanfilippo
Howard M Proskin
Joseph M Blondeau
Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
PLoS ONE
author_facet Heleen H DeCory
Christine M Sanfilippo
Howard M Proskin
Joseph M Blondeau
author_sort Heleen H DeCory
title Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
title_short Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
title_full Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
title_fullStr Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
title_full_unstemmed Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
title_sort characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2020-01-01
description <h4>Background/purpose</h4>To date, studies examining polymicrobial infections in ocular disease have mostly been limited to keratitis or endophthalmitis. We characterized polybacterial infections compared to monobacterial infections in prior clinical studies evaluating besifloxacin ophthalmic suspension 0.6% for the treatment of bacterial conjunctivitis and report on associated microbiological outcomes.<h4>Methods</h4>In this post-hoc analysis, microbiological data for subjects with conjunctivitis due to one or more than one bacterial species in three previous studies (two vehicle-, one active-controlled) of besifloxacin were extracted. Bacterial species identified at baseline were deemed causative if their colony count equaled or exceeded species-specific prespecified threshold criteria. In subjects with polybacterial infections, the fold-increase over threshold was used to rank order the contribution of individual species. Baseline pathogens and their minimum inhibitory concentrations (MICs) for common ophthalmic antibiotics were compared by infection type, as were microbial eradication rates following treatment with besifloxacin.<h4>Results</h4>Of 1041 subjects with culture-confirmed conjunctivitis, 17% had polybacterial and 83% had monobacterial conjunctivitis at baseline. In polybacterial compared to monobacterial infections, Haemophilus influenzae and Streptococcus pneumoniae were identified less frequently as the dominant infecting species (P = 0.042 and P<0.001, respectively), whereas Streptococcus mitis/S. mitis group was identified more frequently as dominant (P<0.001). Viral coinfection was also identified more frequently in polybacterial infections (P<0.001). Staphylococcus aureus was the most common coinfecting species in polybacterial infections and the second most common dominant species in such infections. With few exceptions, MICs for individual species were comparable regardless of infection type. Clinical microbial eradication rates with besifloxacin were high regardless of infection type (P≤0.016 vs vehicle at follow-up visits).<h4>Conclusions</h4>Approximately one in five subjects with bacterial conjunctivitis are infected with more than one bacterial species underscoring the need for a broad-spectrum antibiotic for such infections. Besifloxacin treatment resulted in robust eradication rates of these infections comparable to monobacterial infections.<h4>Trial registration</h4>NCT000622908, NCT00347932, NCT00348348.
url https://doi.org/10.1371/journal.pone.0237603
work_keys_str_mv AT heleenhdecory characterizationofbaselinepolybacterialversusmonobacterialinfectionsinthreerandomizedcontrolledbacterialconjunctivitistrialsandmicrobialoutcomeswithbesifloxacinophthalmicsuspension06
AT christinemsanfilippo characterizationofbaselinepolybacterialversusmonobacterialinfectionsinthreerandomizedcontrolledbacterialconjunctivitistrialsandmicrobialoutcomeswithbesifloxacinophthalmicsuspension06
AT howardmproskin characterizationofbaselinepolybacterialversusmonobacterialinfectionsinthreerandomizedcontrolledbacterialconjunctivitistrialsandmicrobialoutcomeswithbesifloxacinophthalmicsuspension06
AT josephmblondeau characterizationofbaselinepolybacterialversusmonobacterialinfectionsinthreerandomizedcontrolledbacterialconjunctivitistrialsandmicrobialoutcomeswithbesifloxacinophthalmicsuspension06
_version_ 1714804367442313216